KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Depreciation & Amortization (CF) (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 34.52% to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.8 million through Dec 2025, up 154.87% year-over-year, with the annual reading at $40.8 million for FY2025, 154.87% up from the prior year.
  • Depreciation & Amortization (CF) hit $3.8 million in Q4 2025 for Castle Biosciences, down from $3.8 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $29.8 million in Q1 2025 to a low of $233000.0 in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $4.2 million across 5 years, with a median of $3.1 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 823.18% in 2022 and later crashed 34.52% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $1.5 million in 2021, then skyrocketed by 95.8% to $2.8 million in 2022, then rose by 13.48% to $3.2 million in 2023, then skyrocketed by 78.91% to $5.8 million in 2024, then plummeted by 34.52% to $3.8 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CSTL at $3.8 million in Q4 2025, $3.8 million in Q3 2025, and $3.4 million in Q2 2025.